At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,551 enrolled
Drug / intervention
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live +2 morebiological
Likely dose
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Selection Study in Healthy Children Comparing Measles Mumps, Rubella, and Varicella (ProQuad) Vaccine to M-M-R II Given Concomitantly With Process Upgrade Varicella Vaccine (PUVV) in Separate Injections
In Brief
A Phase 2 clinical trial evaluating Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: M-M-R II, and 1 other intervention for Measles and 3 related conditions. Completed, enrolled 1,551 participants.
Detailed Summary
A Study comparing three different doses of ProQuad to concomitant administration of M-M-R II and PUVV (Process Upgrade Varicella Vaccine) vaccines.
Study Details
Timeline
Phase 2CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 1999
Primary CompletionApr 2000
Study CompletionSep 2000
First PostedSep 2009
TodayJul 2026
First PostedSep 29, 2009
Enrollment StartApr 1, 1999
Primary CompletionApr 1, 2000
Study CompletionSep 1, 2000
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.8 years ago
Interventions
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Livebiological
a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
Comparator: M-M-R IIbiological
A single 0.5 mL subcutaneous injection at Day 0
Comparator: PUVVbiological
A single 0.5 mL subcutaneous injection at Day 0